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Inna Belfer
Departments of Medicine & Human Genetics, University of Pittsburgh, Pittsburgh, PA 15213, United StatesIn EBioMedicineMeng et al. (2015a) reported the results from their
second genome-wide association study on neuropathic pain that
aimed to identify novel genetic factors contributing to neuropathic
pain in diabetic patients. The ﬁrst study (Meng et al., 2015b) published
earlier this year in the European Journal of Pain identiﬁed a cluster in the
Chr8p21.3, next toGFRA2 gene locus, associatedwith cases of neuropathic
pain deﬁned as diabetic patientswith a prescription history of at least one
of ﬁve drugs speciﬁcally indicated for the treatment of neuropathic pain
and in whommonoﬁlament test result was positive for sensory neurop-
athy in at least one foot. The narrow-sense heritability of this phenotype
was 11.00%. That study conﬁrmed that diabetic neuropathic pain is a
genetically controlled trait. In the second study in a larger sample the
authors found sex-speciﬁc loci for men (a cluster in the Chr1p35.1;
TLR12P-ZSCAN20) and women (a cluster in the Chr8p23.1, next to
HMGB1P46) associated with the same phenotype, and men had higher
narrow-sense heritability than women (28.5% vs. 16.7%, respectively)
(Meng et al., 2015a). This is the ﬁrst evidence for the sex-speciﬁc contri-
bution of genetic factors to diabetic neuropathic pain.
Although the association with newly-identiﬁed markers didn't
reach conservative GWAS-level of statistical signiﬁcance the data are
still very interesting and worthy of further investigation in follow-up
studies. Sex-speciﬁc genetic effects are of particular interest in the light
of recently reported evidence of many “pain genes” inﬂuencing pain
perception in men and women in different ways (Belfer, 2013). Some
polymorphic alleles protect one sex from pain and predispose another
to more severe or more chronic pain. For example, female carriers of
minor allele of A118G genotype in OPRM1 gene encoding mu opioid
receptor had 2.3 times as much sciatic pain as male carriers of this allele
twelve months after lumbar disc herniation demonstrating a slower
recovery rate (Olsen et al., 2012). These data suggest that OPRM1 G
allele increases the pain intensity in women, but protects men showing
sex-antagonistic effects. Other genes may contribute to pain phenotypes
in both sexes but to the different degree having sex-biased effects. For in-
stance, COMT gene encoding catechol-O-methyltransferase, the enzyme
metabolizing catecholamine neurotransmitters, contributes to pain be-
havior in a sexually dimorphic way: it controls many experimental and
clinical pain phenotypes much stronger in women than in men (Belfer
et al., 2013; Belfer & Segall, 2011). Overall, low COMT activity (as deter-
mined by gene functional variants) leads to more severe pain in women
predominantly. Furthermore, the particular gene × sex interaction may
be pain modality-speciﬁc (Belfer et al., 2013).http://dx.doi.org/10.1016/j.ebiom.2015.08.038
2352-3964/© 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NThese discoveries provide insight into biologicalmechanisms under-
lying the observed sex differences in pain prevalence, related behaviors,
and analgesic response (Belfer, 2013; Bartley & Fillingim, 2013). Genetic
effects may trigger speciﬁc aetiological and risk factors such as endoge-
nous opioid functioning, sex hormones and psychosocial processes.
These effects have high clinical relevance since they may explain the
observed sex differences in responsivity to pharmacological and non-
pharmacological pain interventions (Bartley & Fillingim, 2013). There-
fore sex-speciﬁc genetic effects should be considered in pain pharmaco-
genetics studies since they may inform future efforts to develop novel
sex-speciﬁc pain medicine.
All together the ﬁndings presented in Meng et al. (Meng et al.,
2015a) advance our knowledge on genetics on human pain including
neuropathic pain and painful diabetic neuropathy in particular. Further
elucidation of genetic control of sex-speciﬁc vulnerability to more
severe or more chronic pain is an essential step forward personalized
(gender-speciﬁc) approaches to pain management.
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